These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 12047872)

  • 1. Engineering cellular microenvironments to improve cell-based drug testing.
    Bhadriraju K; Chen CS
    Drug Discov Today; 2002 Jun; 7(11):612-20. PubMed ID: 12047872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The application of engineered liver tissues for novel drug discovery.
    Lin C; Ballinger KR; Khetani SR
    Expert Opin Drug Discov; 2015 May; 10(5):519-40. PubMed ID: 25840592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biofabrication of a three-dimensional liver micro-organ as an in vitro drug metabolism model.
    Chang R; Emami K; Wu H; Sun W
    Biofabrication; 2010 Dec; 2(4):045004. PubMed ID: 21079286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering hepatocyte functional fate through growth factor dynamics: the role of cell morphologic priming.
    Semler EJ; Moghe PV
    Biotechnol Bioeng; 2001 Dec; 75(5):510-20. PubMed ID: 11745126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of epigenetic modifiers in extended cultures of functional hepatocyte-like cells derived from human neonatal mesenchymal stem cells.
    Cipriano M; Correia JC; Camões SP; Oliveira NG; Cruz P; Cruz H; Castro M; Ruas JL; Santos JM; Miranda JP
    Arch Toxicol; 2017 Jun; 91(6):2469-2489. PubMed ID: 27909741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microengineered liver tissues for drug testing.
    Khetani SR; Berger DR; Ballinger KR; Davidson MD; Lin C; Ware BR
    J Lab Autom; 2015 Jun; 20(3):216-50. PubMed ID: 25617027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of cell culture and microfabrication technology.
    Park TH; Shuler ML
    Biotechnol Prog; 2003; 19(2):243-53. PubMed ID: 12675556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A robust high-throughput sandwich cell-based drug screening platform.
    Zhang S; Tong W; Zheng B; Susanto TA; Xia L; Zhang C; Ananthanarayanan A; Tuo X; Sakban RB; Jia R; Iliescu C; Chai KH; McMillian M; Shen S; Leo H; Yu H
    Biomaterials; 2011 Feb; 32(4):1229-41. PubMed ID: 20971505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An integrative biology approach for analysis of drug action in models of human vascular inflammation.
    Kunkel EJ; Dea M; Ebens A; Hytopoulos E; Melrose J; Nguyen D; Ota KS; Plavec I; Wang Y; Watson SR; Butcher EC; Berg EL
    FASEB J; 2004 Aug; 18(11):1279-81. PubMed ID: 15208272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines - a report on the Vitrocellomics EU-project.
    Mandenius CF; Andersson TB; Alves PM; Batzl-Hartmann C; Björquist P; Carrondo MJ; Chesne C; Coecke S; Edsbagge J; Fredriksson JM; Gerlach JC; Heinzle E; Ingelman-Sundberg M; Johansson I; Küppers-Munther B; Müller-Vieira U; Noor F; Zeilinger K
    Altern Lab Anim; 2011 May; 39(2):147-71. PubMed ID: 21639679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity.
    De Bruyn T; Chatterjee S; Fattah S; Keemink J; Nicolaï J; Augustijns P; Annaert P
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):589-616. PubMed ID: 23452081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered Liver Platforms for Different Phases of Drug Development.
    Ware BR; Khetani SR
    Trends Biotechnol; 2017 Feb; 35(2):172-183. PubMed ID: 27592803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topographical and physicochemical modification of material surface to enable patterning of living cells.
    Jung DR; Kapur R; Adams T; Giuliano KA; Mrksich M; Craighead HG; Taylor DL
    Crit Rev Biotechnol; 2001; 21(2):111-54. PubMed ID: 11451046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microprinting of liver micro-organ for drug metabolism study.
    Chang RC; Emami K; Jeevarajan A; Wu H; Sun W
    Methods Mol Biol; 2011; 671():219-38. PubMed ID: 20967633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application of human embryonic stem cell technologies to drug discovery.
    Sartipy P; Björquist P; Strehl R; Hyllner J
    Drug Discov Today; 2007 Sep; 12(17-18):688-99. PubMed ID: 17826681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling of extracellular matrix as an effector of human hepatocyte phenotype in primary cell culture.
    Page JL; Johnson MC; Olsavsky KM; Strom SC; Zarbl H; Omiecinski CJ
    Toxicol Sci; 2007 Jun; 97(2):384-97. PubMed ID: 17329237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput screening of cell responses to biomaterials.
    Yliperttula M; Chung BG; Navaladi A; Manbachi A; Urtti A
    Eur J Pharm Sci; 2008 Oct; 35(3):151-60. PubMed ID: 18586092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem-cell derived hepatocyte-like cells for the assessment of drug-induced liver injury.
    Donato MT; Tolosa L
    Differentiation; 2019; 106():15-22. PubMed ID: 30844688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering in vitro microenvironments for cell based therapies and drug discovery.
    Cigognini D; Lomas A; Kumar P; Satyam A; English A; Azeem A; Pandit A; Zeugolis D
    Drug Discov Today; 2013 Nov; 18(21-22):1099-108. PubMed ID: 23806976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense and RNAi: powerful tools in drug target discovery and validation.
    Lavery KS; King TH
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):561-9. PubMed ID: 12951819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.